The University of Angers is an institution of higher learning situated in the town of the same name, in western France. It was founded in 1356, closed down in 1793, and reestablished in 1971.The pre-revolutionary institution is sometimes looked upon as the precedent institution of the Catholic University of the West, though, as both popes and kings have granted charters to the old University of Angers, it is not a clear predecessor to either of the current Universities in Angers. Wikipedia.
French Institute of Health, Medical Research, Montpellier University, Assistance Publique Hopitaux De Paris, University Paris Est Creteil and University of Angers | Date: 2016-10-17
The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.
University of Angers | Date: 2016-12-02
This invention relates to method of diagnosing the presence and/or severity of a liver pathology and/or of monitoring the effectiveness of a curative treatment against a liver pathology in an individual, leading to a score, comprising the combination, of at least one marker from a blood test and of at least one data issued from a physical method of diagnosing liver fibrosis, said physical method being further defined as elastometry, said combination being performed through a mathematical function.
University of Angers | Date: 2015-04-08
An in vitro prognostic method for assessing the risk of death or of liver-related event in a subject, includes: a) obtaining at least one, preferably 2, of the following variables from the subject: i. biomarkers measured in a sample from the subject; ii. clinical data; iii. binary markers; iv. blood test results; b) optionally obtaining at least one blood test result by univariate combination, preferably with a binary logistic regression, of the at least one variable obtained in step a), the blood test not being a Fibrotest, c) obtaining at least one physical data from medical imaging or clinical measurement, from elastometry, or Vibration Controlled Transient Elastography, and d) mathematically combining in a multivariate time-dependent model the variable obtained in step a) and/or the at least one blood test result obtained in step b); and the at least one physical data, obtained in step c) thereby obtaining a prognostic score.
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 3.83M | Year: 2016
Organic solar cells (OSCs) have the potential to become an environmental friendly, inexpensive, large area and flexible photovoltaics technology. Their main advantages are low process temperatures, the potential for very low cost due to abundant materials and scalable processing, and the possibility of producing flexible devices on plastic substrates. To improve their commercialization capacity, to compete with established power generation and to complement other renewable energy technologies, the performance of state-of-the-art OSCs needs to be further improved. Our goals within SEPOMO Spins in Efficient Photovoltaic devices based on Organic Molecules are to bring the performance of OSCs forward by taking advantage of the so far unexplored degree of freedom of photogenerated species in organic materials, their spin. This challenging idea provides a unified platform for the excellent research to promote the world-wide position of Europe in the field of organic photovoltaics and electronics, and to train strongly motivated early stage researchers (ESRs) for a career in science and technology oriented industry that is rapidly growing. Our scientific objectives are to develop several novel routes to enhance the efficiency of OSC by understanding and exploiting the electronic spin interactions. This will allow us to address crucial bottlenecks in state-of-the-art OSCs: we will increase the quantum efficiency by reducing the dominant recombination losses and by enhancing the light harvesting and exciton generation, e.g. by means of internal upconversion of excited states. Our ESRs will be trained within this interdisciplinary (physics, chemistry, engineering) and intersectoral (academia, R&D center, enterprise) consortium in highly relevant fundamental yet application-oriented research with the potential to commercialise the results. The hard and soft skills learned in our network are central for the ESRs to pursue their individual careers in academics or industry.
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: NMP.2013.1.2-2 | Award Amount: 10.45M | Year: 2013
Resistance to traditional antibiotics is a rapidly increasing problem that in a few years could make infections impossible to treat and bring the state of medical care back to the pre-antibiotic era from the beginning of the last century. Antimicrobial peptides (AMPs) have a huge potential as new therapeutics against infectious diseases as they are less prone to induce resistance due to their fast and non-specific mechanism of action. The aim of FORMAMP is to explore a number of innovative formulation and delivery strategies based on nanotechnology in order to improve the efficiency and stability of AMPs in clinical development. Functional delivery systems that can be applied directly on the infected site will be developed for treatment of infections in skin and burn wounds, as well as lung infections caused by Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa and Mycobacterium tuberculosis (MTB). Formulation and delivery strategies to prevent and treat biofilm formation related to these conditions will be developed. Different nanoformulation platforms, particularly promising for peptide delivery, controlled release strategies and technologies against proteolytic degradation of peptides will be evaluated in the project. These include lipid-based systems such as lipidic nanocapsules, polymer-based structures such as dendrimers and microgels as well as nanostructured mesoporous silica. The possibility to formulate the nanostructured materials into efficient drug delivery systems such as a topical spray or gel and pulmonary aerosol will be evaluated. The effect of nanoformulated AMPs will be evaluated with state-of-the art in vitro models and in vivo models. The results of this interdisciplinary project will generate efficient treatment strategies combatting one of the largest threats to our health care system today, reducing healthcare costs and expand the growth of European enterprises within the field of pharmaceutics and nanomaterials.
Roncali J.,University of Angers |
Leriche P.,University of Angers |
Blanchard P.,University of Angers
Advanced Materials | Year: 2014
An overview of some recent developments of the chemistry of molecular donor materials for organic photovoltaics (OPV) is presented. Although molecular materials have been used for the fabrication of OPV cells from the very beginning of the field, the design of molecular donors specifically designed for OPV is a relatively recent research area. In the past few years, molecular donors have been used in both vacuum-deposited and solution-processed OPV cells and both fields have witnessed impressive progress with power conversion efficiencies crossing the symbolic limit of 10 %. However, this progress has been achieved at the price of an increasing complexity of the chemistry of active materials and of the technology of device fabrication. This evolution probably inherent to the progress of research is difficult to reconcile with the necessity for OPV to demonstrate a decisive economic advantage over existing silicon technology. In this short review various classes of molecular donors are discussed with the aim of defining possible basic molecular structures that can combine structural simplicity, low molecular weight, synthetic accessibility, scalability and that can represent possible starting points for the development of simple and cost-effective OPV materials. Various classes of molecules used as donor materials in heterojunction organic solar cells are presented. Special emphasis is placed on molecular structures that combine low molecular weight, (in general inferior to 500) structural simplicity and synthetic accessibility with reasonable yield. Such systems are discussed as possible working structures for the development of simple and cost-effective materials for organic photovoltaics. © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Girtan M.,University of Angers
Solar Energy Materials and Solar Cells | Year: 2012
In this paper we present the physical properties of two types of multilayer structures: ITO/metal/ITO and ZnO/metal/ZnO obtained by successive sputtering depositions of metallic targets (In:Sn, Zn, Ag, Au) in reactive atmosphere (for oxide films) and under inert atmosphere (for metallic interlayer films). Very good quality transparent conducting thin films structures (ρ=2×10 -5 Ω cm, T∼90%) were obtained. The morphological, optical and electrical properties were analyzed and compared for the multilayer films deposited in identical conditions on glass and PET substrates. The influence of substrate nature on the morphological properties is more pronounced in the case of zinc oxide films. The Haake figures of merit at λ=550 nm are comprised between 4×10 -3 Ω -1 and 29×10 3 Ω -1 in function of the nature of the metallic interlayer. The stability of electrical properties with the temperature of the oxide/metal/oxide films is remarkable in comparison with the usual behavior of single oxide films. © 2012 Elsevier B.V. All rights reserved.
University of Angers, French Institute of Health, Medical Research and McGill University | Date: 2016-08-05
The present invention provides a new drug to treat malignant glioma, which is the most prevalent type of primary tumor of the central nervous system (CNS). The present invention indeed shows that the isolated NFL-TBS_(40-63 )peptide is highly specific for glioma cells, in which it triggers apoptosis. It is therefore presented here for use in a method for treating malignant glioma. The present invention further relates to the use of the NFL-TBS_(40-63 )peptide for detecting specifically glioma cells either in vivo, or in vitro, or for addressing chemical compounds to said tumor cells.
University of Angers | Date: 2016-02-03
The present invention relates to a method for displaying an easy-to-understand medical image, comprising the steps of:a. obtaining a medical image,b. identifying at least one feature on the image of step (a),c. generating at least one mask highlighting the at least one feature,d. displaying at least one easy-to-understand medical image including at least one mask on which the at least one feature identified in step (b) is highlighted.
University of Angers and University of Nantes | Date: 2016-10-12
The present invention relates to a non-invasive method for assessing the presence and/or severity of varices selected from gastric and esophageal varices in a liver disease patient, wherein said method comprises:(a) carrying out a non-invasive test for assessing the severity of a hepatic lesion or disorder, wherein said non-invasive test results in a value, and(b) comparing the value obtained at step (a) with cut-offs of said non-invasive test for assessing the presence and/or severity of varices selected from gastric and esophageal varices.